Ferrous sulfate oral solution in young children with iron deficiency anemia: An open‐label trial of efficacy, safety, and acceptability

Abstract

A 2 mg/kg daily dose of the new oral ferrous sulfate heptahydrate solution provides substantial therapeutic benefit with high levels of tolerability in young children who have mild or moderate IDA.